The Cambridge, Massachusetts-based precision medicine firm hopes to translate molecular information into therapies for chronic kidney diseases.
The researchers identified new combinations of mutated genes and drugs that could provide the platform for future cancer therapies.
Backed by $12 million from a recent Series A financing and a strategic partnership with Thermo Fisher Scientific, the Ann Arbor, Michigan-based firm plans to sequence the tumors of 100,000 advanced cancer patients over three years.
Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.
Portable's mobile app allows patients to capture genotype, phenotype, and other data, and potentially profit from sharing it with interested third parties.
Using Luminex's FlexMap detector, the method allows quantification of cells in a mixture of up to hundreds of individual cells lines treated with drugs in vitro.
Under the terms of the agreement, Insilico Medicine will integrate unspecified data assets and the staff of Belgian bioinformatics company InSilico Screen.
TwoXar's business is based on licensing drug candidates to pharma identified using proprietary algorithms for exploring disease-compound associations.
The company will use some of the funds to set up a new research laboratory within the US to better support collaborations with pharma and biotech.
NEW YORK (GenomeWeb News) – A consortium comprising six industry players and academic partners has been created to identify kinases that could serve as drug targets.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.